Dolmans Marie-Madeleine, Masciangelo Rossella
Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium -
Department of Gynecology, Cliniques Universitaires Saint-Luc, Brussels, Belgium -
Minerva Ginecol. 2018 Aug;70(4):436-443. doi: 10.23736/S0026-4784.18.04233-8. Epub 2018 Apr 11.
Improvements in cancer treatments have increased the chances of survival of young cancer patients, but have given rise to other issues, like premature ovarian insufficiency and infertility. Preservation and subsequent restoration of ovarian function in these patients is now possible thanks to ovarian tissue cryopreservation and transplantation. However, safety concerns about the possible presence of cancerous cells in the tissue to be cryopreserved must be addressed. Indeed, reimplantation of malignant cell-contaminated ovarian tissue could potentially lead to recurrence of the primary disease. This review of the existing literature aims to evaluate the risk of reintroducing malignant cells in pathologies that represent the main indications for ovarian tissue cryopreservation. Experimental studies applying molecular analyses as well as xenografting investigation have proved that hematologic and ovarian malignancies are those at greatest risk of ovarian involvement, and hence recurrence upon reimplantation of frozen-thawed ovarian tissue. Preimplantation analysis using highly sensitive techniques and disease-specific markers is therefore vital in these patients to detect minimal disseminate disease.
癌症治疗的进步提高了年轻癌症患者的生存几率，但也引发了其他问题，如卵巢早衰和不孕。由于卵巢组织冷冻保存和移植，现在这些患者的卵巢功能保存及后续恢复成为可能。然而，必须解决对拟冷冻保存的组织中可能存在癌细胞的安全担忧。确实，重新植入受恶性细胞污染的卵巢组织可能会导致原发性疾病复发。本现有文献综述旨在评估在那些构成卵巢组织冷冻保存主要适应症的病症中重新引入恶性细胞的风险。应用分子分析以及异种移植研究的实验性研究已证明，血液系统恶性肿瘤和卵巢恶性肿瘤是卵巢受累风险最大的肿瘤，因此在冻融卵巢组织重新植入后会复发。因此，对于这些患者而言，使用高度敏感技术和疾病特异性标志物进行植入前分析对于检测微小播散性疾病至关重要。
